PTX (PTX) Fair Value & Analysis
Healthcare · Market cap A$76.8M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 6 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0500 to A$0.1346 (+169.3%) since Jun 24, 2026. Share price −9.5% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0394 – A$0.1034 · fair‑value band A$0.0818 – A$0.1742 · the A$0.0660 price screens below the A$0.1346 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PTX (PTX) currently trades at A$0.0660, while our model-based Fair Value estimate is A$0.1346 — implying the stock looks roughly 104.0% undervalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$4.3M. Revenue declined 7.3% year over year. It earns a return on equity of -54.3%. The balance sheet holds a net cash position of A$6.9M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PTX reported revenue of A$4.4M in FY2025 versus A$1.2M in FY2021, a compound +38.5%/yr. Reported net income was −A$7.3M in FY2025.
Is PTX fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PTX (PTX) undervalued?
What is the fair value of PTX?
What is the quality score of PTX?
What is the revenue of PTX (PTX)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.